GMV has teamed up with the Extremadura Health Service to develop the PoPS (Personalized Oriented Drug Prescription System) tool

Can digital technology applied to clinical practice assist healthcare professionals in prescribing individualized pharmacological treatments? This health and sustainability challenge involves determining whether a specific medication will be effective for a patient and, if so, at what dosage, using technological tools to support healthcare professionals and avoid side effects and adverse reactions. The Extremadura Health Service (SES) has addressed this challenge through its leadership on  MedeA, a pioneering project in Spain, supported by the expertise and advanced algorithmic developments of technology multinational GMV. Specifically, GMV is actively participating in the collaborative project to create a personalized drug prescription support tool called PoPS.

The goal of MedeA is to develop technological systems that support clinical decision-making, including a Personalized Oriented Drug Prescription System.  This initiative is disruptive for three reasons: 1) its funding approach through public-private collaboration in innovative public biosanitary procurement; 2) its focus on a single healthcare system such as the Extremadura Health Service (SES), where the project is conceived as a comprehensive, cross-cutting system for the entire population, minimizing healthcare and social inequities; 3) it empowers physicians with a digitally supported prescription tool, enabling personalized therapy  decisions  by considering genetic information within the patient's medical history when determining the optimal drug combination.